InvivoChem Cat #:V14470CAS #:951395-08-7Purity >=98%Description: Tafamidis meglumine (also known as Fx-1006 or PF-06291826), a potent and selectivetransthyretin (TTR) stabilizer, is a drug for the amelioration oftransthyretin-related hereditary amyloidosis (also familial amyloidpolyneuropathy, or FAP), a rare but deadly neurodegenerative disease. Itshows comparable potency and efficacy to the mutumant homotetramersV30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 uM.Tafamidis inhibits amyloidogenesis. The drug was approved by theEuropean Medicines Agency in November 2011 and by the JapanesePharmaceuticals and Medical Devices Agency in September 2013. Tafamidisfunctions by kinetic stabilization of the correctly folded tetramericform of the transthyretin (TTR) protein.
References: Proc Natl Acad Sci U S A, 2012. 109(24): p. 9629-34.
Related CAS: 951395-08-7 (meglumine salt) 594839-88-0 (free acid)
Description: Tafamidis meglumine (also known as Fx-1006 or PF-06291826), a potent and selectivetransthyretin (TTR) stabilizer, is a drug for the amelioration oftransthyretin-related hereditary amyloidosis (also familial amyloidpolyneuropathy, or FAP), a rare but deadly neurodegenerative disease. Itshows comparable potency and efficacy to the mutumant homotetramersV30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 uM.Tafamidis inhibits amyloidogenesis. The drug was approved by theEuropean Medicines Agency in November 2011 and by the JapanesePharmaceuticals and Medical Devices Agency in September 2013. Tafamidisfunctions by kinetic stabilization of the correctly folded tetramericform of the transthyretin (TTR) protein.
References: Proc Natl Acad Sci U S A, 2012. 109(24): p. 9629-34.
Related CAS: 951395-08-7 (meglumine salt) 594839-88-0 (free acid)